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the ground truth. The major fracture trends, viz. E–W, 
NE–SW and NW–SE and the associated smaller linea-
ments and their permeabilities are varying at different 
places and concentrated in the eastern side. In addition to 
the dissection of the dykes at different places, the connec-
tivity of the fractures in the subsurface had allowed the 
water table to be percolated down into the deeper extents, 
especially around the epicentre. Extensive research on the 
interaction of hydrological activities and seismicity had 
shown that pore-pressure changes due to reservoir filling 
or water-level changes in a suitable geologic setting can 
generate seismicity22. Therefore, it is concluded that signi-
ficant amount of base flow in this part of the area had  
resulted in hydro-loading, following heavy rains during 
the monsoon period of 2010 and was responsible for the 
micro-seismicity. 
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Phenytoin is an antiepileptic drug which has been 
used in the present study to assess its effect on deve-
lopmental toxicity from egg to adult eclosion and also 
life-history traits in Drosophila melanogaster. Flies 
were reared on media supplemented with different 
doses of phenytoin. The dose-dependent developmen-
tal delay, reduced pupal and adult size reduced adult 
eclosions, minimum larval, adult mortality, but sig-
nificant pupal mortality was observed with incomplete 
pupal eclosion. The data show reduction in fecundity 
for life-history traits, but differences are not statisti-
cally significant for fertility and lifespan. The present 
study reveals that on exposure to phenytoin pre-adult 
stages are prone to developmental toxicity than the 
treated adult. 
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PHENYTOIN is a first-line antiepileptic drug (AED) which 
is being widely prescribed throughout the world for more 
than 70 years as an anticonvulsant to treat epilepsy and 
seizures, both in acute and chronic conditions. Control of 
epilepsy with phenytoin can be a difficult and lengthy 
process because of the narrow therapeutic index of the 
drug and the wide inter-individual range of doses requi-
red1. Children born to mothers taking antiseizure drugs 
have an increased risk (twofold) of congenital malforma-
tions. Use of phenytoin during pregnancy has been impli-
cated in Foetal hydantoin syndrome (skeletal, CNS, limb 
and orofacial defects)2. 
 Drosophila melanogaster has been a model for exa-
mining fundamentally important problems in biology,  
especially developmental biology, neurobiology and neu-
ropharmacology3,4. The use of animal tissues for toxico-
logical tests now involves two fundamental concepts: 
science and ethics, leading to a search for alternative  
approaches. Nowadays, species of Drosophila are model 
organisms for toxicological studies, as they are well  
defined in terms of their genetics, biological development 
and genome. Besides, their use is recommended by the 
European Centre for Validation of Alternative Methods, 
which promotes the scientific and regular acceptance of 
alternative experimental methods5. Once a molecule is 
identified as a potential drug, detection of adverse drug 
reactions is one of the key components of its develop-
ment. D. melanogaster is used to screen for reproductive 
fitness and developmentl toxicity. Compared with other 
non-mammalian models, D. melanogaster has many simi-
larities with the mammalian reproductive system, includ-
ing putative sex hormones and conserved proteins 
involved in genitourinary development. Furthermore, D. 
melanogaster would present significant advantages in 
time efficiency and cost-effectiveness compared to 
mammalian models.  
 Genotoxic substances such as diethylstilbestrol, diphe-
nylhydantoin, imipramine, testosterone and tolbutamide 
have shown a high teratogenic potential, whose effects 
were evident in muscles and neurons in D. melano-
gaster6. To understand the effect of phenytoin on D. 
melanogaster, the drug was administered separately to 
pre-adult (eggs) and adult flies. D. melanogaster is being 
studied for its potential to aid in identifying priority 
chemicals for teratologic study7.  
 The method encompasses treating the entire meta-
morphosis period, i.e. from the egg through the larval 
stages to pupa formation, by incorporating the test che-
mical into the medium. Adult females lay eggs that hatch 
as larvae after a day. These larvae grow tremendously 
over the next four days as they voluntarily consume food 
and molt twice. During the final larval instar, larvae stop 
eating, leave the food (wander) and form a puparium,  
signalling the onset of metamorphosis. The duration of 
metamorphosis is four days, after which the adult fly 
emerges. Thus, the life cycle of the fly is such that deve-
lopmental exposure and consumption of phenytoin-
containing food are voluntary, unlike gestational mam-
mals and occurs mostly during the larval stage of develop-
ment. Developmental toxicity was evaluated based on the 
number of days taken for development and number of adults 
eclosed after treating with the drugs in preadult stage. Adult 
flies were systematically examined under a binocular  
microscope for external morphological anomalies.  
 Data from treated flies can be compared with those 
from concurrent untreated flies using statistical tests. The 
external development of flies eliminates the complica-
tions of maternal–placenta–foetal interactions seen in 
mammalian studies8. Reproductive fitness was measured 
in terms of mating propensity, fecundity, fertility and 
longevity in treated adult flies. The report on meth-
otrexate reproductive adverse events in multiple animal 
models, including fruit flies, has been a proof for the use 
of the D. melanogaster model9. The intensive toxicity 
was evaluated by observing phenotype of adults resulting 
after drug treatment and mortality in treated flies. 
 The fly stocks were routinely cultured in standard 
wheat cream agar medium in uncrowded condition at 
22 ± 1°C (rearing temperature), 12 : 12 h light and dark 
periods and relative humidity of 70%. The D. melano-
gaster (oregan k) stocks were obtained from National 
Drosophila Stock Centre, Mysore, India. The test flies 
were cultured in wheat cream agar medium along with 
different concentrations of the epileptic drug phenytoin – 
5, 10 and 15 mg/ml of the medium.  
 Phenytoin (5,5 diphenylhydantoin sodium salt) 99%, 
CAS no: 630-93-3 was obtained from Sigma-Aldrich, dis-
solved in ethanol and water (1 : 1) and added to the  
medium. A modified protocol10 was used for drug stan-
dardization. Standardization of doses was carried out on 
adult mortality for seven days using three doses, viz. low 
dose –5 mg/ml, mid dose –10 mg/ml and high dose  
–15 mg/ml of medium to treat the flies. 
 For preadult treatment, the drug was added to a wheat 
cream agar medium in different doses (5, 10 and 
15 mg/ml). The control cultures were raised on the same 
diet without addition of the drug. Virgin females and un-
mated males which were grown for five days were col-
lected and maintained separately in order to age and then 
transferred to phenytoin-containing medium alongside a 
control. The 5 ml of the medium was placed in 25 × 
100 mm sample tubes and a pair of flies was transferred 
to each vial. Likewise three successive transfers were 
made into fresh food containing phenytoin once in two 
days. Flies were allowed to lay eggs on the medium con-
taining phenytoin in three different doses alongside the 
control and the number of eggs laid was recorded. Dilute 
yeast was added to the same set of vials for the eggs to 
hatch, complete larval and pupal development and for the 
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eclosion of adults11. The number of adult eclosed was  
recorded from the treated (all three doses) and untreated 
(control) vials. Simultaneously, the same sets of vials 
were assessed for the developmental time12 (recorded in 
number of days). Adult flies are systematically examined 
under a binocular microscope for external morphological 
anomalies. Size of larva, pupa and adult was measured 
using micrometry. Adult flies were maintained till the 
mortality and longevity were recorded. 
 For the treatment of adults, unmated male and virgin 
female flies were collected in an uncrowded condition 
and were reared separately for two days. The flies were 
fed with wheat cream agar medium containing phenytoin 
in three different doses (5, 10 and 15 mg/ml) for three 
days. These treated flies were analysed for life-history 
traits such as mating propensity, fecundity, fertility and 
longevity13. The experimental trials for all three doses 
were analysed for four different sets, namely untreated 
male × untreated female (C), treated male × untreated 
female (T1), untreated male × treated female (T2) and 
treated male × treated female (T3).  
 To assess mating propensity, virgin females and un-
mated males were collected on the day of eclosion anaes-
thetized with ether to facilitate sorting of the sexes and 
stored in food vials. Flies were aged for five days in food 
vials for sexual maturity. For each set of experiments, a 
single male and female (single pair mating) was allowed 
to mate in empty glass vials (30 samples) to record the 
duration of courtship and copulation. The time taken by 
male to mount on female (courtship duration), the time 
from mounting to detaching (copulation duration) and the 
mating activity were observed for 60 min. The pairing of 
flies from the time of mounting to detaching was recor-
ded. The pairs which do not mate within a stipulated time 
of 60 min were discarded. 
 The same set of vials which was used to observe mat-
ing propensity was used to assess the fecundity. Soon  
after mating, males from each pair were separated and 
females were transferred into separate vials containing 
fresh food medium. Fecundity was assayed by counting 
the number of eggs laid by the female. Likewise, each 
replicate was transferred successively to the next set of 
fresh food vials containing medium every alternate day 
for six days. Immediately after each transfer, the vials 
were checked for the eggs laid and were counted under 
stereomicroscope. 
 The same set of vials that was used to assess fecundity 
was used to assess fertility (total number of adults 
emerged). The eggs were allowed to hatch and dilute 
yeast was added till pupation. Further, the number of flies 
that emerged from all the experimental trials for each 
dose was recorded13. 
 Longevity was assessed simultaneously using the same 
set of flies along with fecundity and fertility. All the vials 
were observed from the day of adult emergence to record 
the lifespan of the flies. 
 One-way ANOVA was performed for the said life-
history parameters, namely courtship duration, copulation 
duration, fecundity, fertility and longevity. Post-hoc 
Duncan’s Multiple Range Test was conducted to record 
the significant differences. The analysis was performed 
using the Statistical Presentation System Software Pack-
age, SPSS version 15.0.  
 Using D. melanogaster, the effects of growth on medium 
supplemented with 5, 10 and 15 mg/ml phenytoin were 
determined alongside a control. The differences are not 
statistically significant for fecundity (Figure 1 a) in all 
the doses when compared with control. Significant differ-
ence was observed for adult eclosion in high dose 
(P < 0.001) when compared with low dose and control 
(Table 1). 
 The mean developmental time from egg to adult emer-
gence was 11.90 days in control (Figure 1 b). The figure 
also shows extreme values in the mean development time 
of 16.70 days in high dose and 14.80 days in mid dose, 
but the differences are not statistically significant at low 
dose when compared with control.  
 The differences are not statistically significant for size 
(mm) between treated and control larvae, whereas pupal 
size was statistically significant (Figure 2 a) in mid dose 
(2.15 mm) and high dose (2.16 mm) of phenytoin when 
compared to control; but there were no differences at low 
dose. Interestingly, Table 2 shows that the mean adult 
size is significantly reduced in 10 mg/ml (1.88 mm) and 
15 mg/ml (1.89 mm), but not observed in 5 mg/ml when 
compared to control. Drastic changes in size variation 
were observed and recorded in treated flies for pupal and 
adult size (Figure 3 a and c).  
 The eggs treated with higher doses have shown signifi-
cant mortality rates for pupa than larva and adult. The 
percentage of pupal mortality rate was significant at 
41.42 and 40.66 in 10 and 15 mg/ml of medium respec-
tively (Figure 2 b), whereas larval and adult stages have 
not shown significant mortality. Interestingly, the in-
creased pupal mortality was observed with typical pattern 
of partial eclosion (Figure 3 b).  
 Table 3 reveals the mean courtship duration assessed 
on exposure to phenytoin for three different doses in  
untreated and treated experimental trails. The observed 
differences are not statistically significant for courtship 
duration in C, T1, T2 and T3 trials on exposure to different 
doses of phenytoin. The mean copulation duration of  
both untreated and treated trials on exposure to 5, 10 and 
15 mg/ml phenytoin is not statistically significant  
(Table 3). 
 The mean fecundity in different experimental trials (C, 
T1, T2 and T3) on exposure to different doses of phenytoin 
is depicted in Table 4. The data reveal reduced mean 
number of eggs produced in T3 trial where both males 
and females are treated on exposure to 10 and 15 mg/ml 
of medium compared to T1 and T2. The differences are  
significant between treated trials and control at higher 
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Figure 1. Mean (± SE) number of eggs and adults eclosed (a) and development time (b) on exposure to phenytoin. 
 
 
 
Figure 2. Mean (± SE) size (mm) (a) and mortality (%) (b) of larva, pupa and adult on exposure to phenytoin. 
 
Table 1. Mean (± SE) number of eggs, adults and developmental time (days) on exposure to phenytoin 
 Traits 
 
Dose↓ No. of eggs No. of adults eclosed Developmental time 
 
Control (c) 168.80 ± 0.72 156.50 ± 0.64 11.90 ± 0.40 
5 mg/ml (l) 178.60 ± 0.51 162.20 ± 4.58 11.20 ± 0.55 
10 mg/ml (m) 168.80 ± 0.74  76.10 ± 5.43 14.80 ± 0.20 
15 mg/ml (h) 171.30 ± 0.36  56.40 ± 5.83 16.70 ± 0.47 
ANOVA  F = 1.615  F = 47.341  F = 26.266 
  P > 0.203  P < 0.001 P < 0.001 
DMRT c/l, c/h, l/m, l/h c/l, c/m, c/h, l/m, l/h, m/h c/m, c/h, l/m, l/h, m/h 
l, Low dose; m, Mid dose; h, High dose. DMRT, Duncan’s Multiple Range Test. 
 
 
dose. The fecundity has reduced in T3 followed by T1 and 
T2 in 15 mg/ml. Differences are not statistically signifi-
cant for 5 mg/ml of phenytoin exposure in all the four 
experimental trials. 
 The mean fertility is represented in Table 4 for three 
doses of phenytoin exposure (5, 10 and 15 mg/ml) of  
untreated and treated experimental trials. The results 
show negligible difference in the number of adults 
emerging in the trials C, T1, T2 and T3, where both sexes 
treated or untreated, or either the males or females are 
used in all these experimental trials for different doses of 
phenytoin exposure. According to ANOVA, the differ-
ences were not statistically significant for both treated 
and untreated experimental trials on exposure to all the 
doses of phenytoin. 
 Table 4 also shows the mean longevity of flies which 
are treated and untreated for different doses of phenytoin, 
and difference has not been observed for lifespan. Lon-
gevity was not affected much – it relies on an average of 
90 days in 10 mg/ml and 92 days in 15 mg/ml of pheny-
toin exposure. 
 Exposure to anticonvulsant drugs during pregnancy is 
one of the most common potentially teratogenic expo-
sures, occurring in 1 in 250 of pregnancies14. The  
embryotoxic and teratogenic effects of phenytoin have 
also been experimentally demonstrated in rodents15,16. 
Phenytoin and related proteratogens, including the seda-
tive drug thalidomide, are bioactivated by embryonic 
prostaglandin H synthases, lipoxygenases and related  
enzymes to a free radical intermediate, which causes 
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Table 2. Mean (± SE) morphomeristic traits and percentage of morphometric traits of D. melanogaster on exposure to phenytoin 
 Morphomeristic traits (mm) Morphometric traits (%) 
 
Dose Larval size Pupal size Adult size Larval mortality Pupal mortality Adult mortality 
 
Control 3.96 ± 0.053 2.56 ± 0.032 2.55 ± 0.009  7.14 ± 0.422  2.42 ± 0.334 0.29 ± 0.036 
5 mg/ml 3.96 ± 0.051 2.53 ± 0.008 2.50 ± 0.019  8.26 ± 0.204 6.78 ± 0.32 1.34 ± 0.253 
10 mg/ml 3.98 ± 0.047 2.15 ± 0.022 1.88 ± 0.012 14.28 ± 0.339 41.42 ± 0.667 1.98 ± 0.279 
15 mg/ml 3.90 ± 0.055 2.16 ± 0.013 1.89 ± 0.018 18.54 ± 0.326 40.66 ± 0.354 1.62 ± 0.252 
 
Table 3. Mean (± SE) mating propensity of D. melanogaster on exposure to phenytoin 
Traits →  Courtship duration Copulation duration 
 
Dose → (mg/ml) 5 10 15 5 10 15 
Trial ↓       
 
C 6.00 ± 0.93 5.40 ± 0.87 4.70 ± 0.47 21.80 ± 0.96 22.50 ± 0.85 23.30 ± 0.76 
T1 5.20 ± 0.81 5.56 ± 0.84 5.40 ± 1.09 22.60 ± 0.76 23.02 ± 0.67 21.80 ± 0.85 
T2 6.30 ± 1.12 6.02 ± 0.72 5.90 ± 0.78 21.80 ± 0.72 21.90 ± 0.89 23.10 ± 0.83 
T3 4.40 ± 0.65 5.62 ± 0.75 5.50 ± 0.50 22.70 ± 0.75 22.20 ± 0.76 23.12 ± 0.97 
ANOVA F = 0.905 F = 0.114  F = 0.436 F = 0.326  F = 0.372  F = 0.645 
  P > 0.448  P > 0.951 P > 0.729  P > 0.806  P > 0.774  P < 0.591 
DMRT C/T1, C/T3,  C/T2, T1/T2, C/T1, C/T3, C/T1, C/T3, C/T1, C/T2, C/T3, C/T1, T1/T2, 
  T1/T2, T1/T3, T2/T3 T2/T3 C/T2 T1/T2, T2/T3, T1/T2, T1/T3, T2/T3 T1/T3 
C, Untreated♂ × Untreated♀; T1, Treated♂ × Untreated♀; T2, Untreated♂ × Treated♀; T3, Treated♂ × Treated♀. 
 
 
 
Figure 3. Phenotypic variations. a, Reduced pupal size; b, Pupal mortality; c, Reduced adult size of  
D. melanogaster on exposure to phenytoin. 
 
 
embryonic oxidative stress, hydroxyl radical formation 
and oxidative damage to DNA and other cellular macro-
molecules in embryonic tissues17. A study reported that 
dose-dependent increase in embryopathies was caused by 
phenytoin by both maternal and embryonic analyses18. 
 Prenatal exposure to AEDs in humans results in a wide 
range of developmental abnormalities, including growth 
deficiency, developmental delay, reduced size, permanent 
neurobehavioural abnormalities and foetal death19. The 
frequency of major malformations, growth retardation 
and hypoplasia of the midface and fingers, known as an-
ticonvulsant embryopathy, is increased in infants exposed 
to anticonvulsant drugs in utero, but it is not known 
whether the abnormalities were caused due to maternal 
epilepsy or by exposure to anticonvulsant drugs20,21. It is 
also still unknown if phenytoin has a higher risk than 
newer AEDs22.  
 Phenytoin exposure decreased maternal weight during 
gestation as detected in rats23,24. Consistent with these  
observations are studies that found increased resorptions 
and decreased litter size in rabbits25 and decreased litter 
weight in rats26. Decreased foetal weight was observed in 
mice27 as well as decreased whole brain28. Consistent 
with the symptoms of foetal hydantoin syndrome in  
humans, the teratogenicity (cleft palate) of phenytoin was 
documented in mice29. A possible correlation with this 
observation is a detection of altered craniofacial gene  
expression in embryonic mice30. Similar results have 
been expressed in D. melanogaster on exposure to pheny-
toin with drastic dose-dependent developmental delay 
(Figure 1 b), reduced adult eclosion (Figure 1 a) and  
reduction in pupal and adult size (Figure 2 a), with  
significant increase in larval and pupal mortality which in 
turn has led to reduction in adult eclosion.  
 Thus the result emphasizes D. melanogaster as a useful 
model system to uncover the complex etiology of devel-
opment. The metabolic activation of phenytoin to a reactive 
intermediate has been proposed to account for the terato-
genicity and possible genotoxicity2. Antiepileptic medica-
tion use affects reproductive endocrine function, but its 
impact on fertility is not well known31. Men on AEDs 
have been reported to have more sperm abnormalities
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Table 4. Mean (± SE) life-history traits of D. melanogaster on exposure to phenytoin 
Traits → Fecundity Fertility Longevity 
 
Dose → 5 10 15 5 10 15 5 10 15 
Trials ↓ 
 
C 186.50 ± 2.43 180.50 ± 2.43 182.50 ± 1.23 180.30 ± 3.10 178.30 ± 3.10 179.01 ± 0.97 89.12 ± 1.63 93.14 ± 1.28 86.30 ± 0.36 
T1 180.70 ± 3.35 177.50 ± 3.61 140.61 ± 5.73 172.90 ± 4.34 166.30 ± 5.67 123.34 ± 4.08 93.56 ± 0.86 88.94 ± 1.97 89.20 ± 1.87 
T2 171.70 ± 5.01 174.20 ± 4.49 154.35 ± 5.57 161.80 ± 4.79 158.40 ± 4.19 131.03 ± 4.34 87.04 ± 1.76 85.28 ± 1.49 86.40 ± 0.43 
T3 180.03 ± 4.30 156.70 ± 6.42 112.41 ± 5.03 164.38 ± 4.78 144.10 ± 7.02  92.56 ± 5.52 90.14 ± 1.43 90.76 ± 0.65 92.56 ± 1.74 
ANOVA F = 1.789 F = 0.575 F = 7.298 F = 1.299 F = 0143 F = 4.910 F = 0.802 F = 0.675 F = 1.232 
  P > 0.167 P > 0.635 P < 0.012 P > 0.290 P > 0.934 P < 0.002 P > 0.103 P > 0.342 P > 0.421 
DMRT C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, C/T1, C/T2, 
  C/T3, T1/T2,  C/T3, T1/T2, C/T3, T1/T3, C/T3, T1/T2, C/T3, T1/T2, C/T3, T1/T2, C/T3, T2/T1, C/T3, T2/T1, C/T3, T2/T1, 
  T2/T3 T1/T3, T2/T3 T2/T3 T1/T3, T2/T3 T1/T3, T2/T3 T1/T3, T2/T3 T2/T3, T3/T1 T2/T3, T3/T1 T2/T3, T3/T1 
C, Untreated♂ × Untreated♀; T1, Treated♂ × Untreated♀; T2, Untreated♂ × Treated♀; T3, Treated♂ × Treated♀. 
 
 
 
Figure 4. Mean (± SE) courtship duration (a) and copulation duration (b) for three doses of phenytoin in different experimental crosses. 
 
 
 
Figure 5. Mean (± SE) fecundity (a), fertility (b) and longevity (c) for three doses of phenytoin in different experimental crosses. 
 
and lower sperm motility and also fertility rates have re-
duced after long-term treatment with different AEDs32. 
The effect of AED use on the number of children has not 
been widely studied; the number of children was lower in 
patients on AEDs than in untreated patients, or subjects 
without epilepsy. Women with epilepsy, particularly 
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those taking AEDs, are at increased risk for endocrine 
dysfunction and infertility33. It has been claimed that fer-
tility rates have been reduced after long-term treatment 
with different AEDs34,35.  
 The present study shows that there was no significant 
difference in mating propensity (Figure 4), but reduction 
in fecundity (Figure 5 a) in T3 experimental trial, where 
both males and females were treated with higher doses 
(10 and 15 mg/ml). Also, there was minimum reduction 
in T1 and T2 where either the males or females were 
treated in each trial, but no effect on fecundity with low 
dose of phenytoin exposure compared to trial C, where 
both males and females were untreated. The difference 
has not been observed for fertility (Figure 5 b) in all the 
experimental trials on exposure to different doses of 
phenytoin. Longevity (Figure 5 c) has not been affected 
when treated with different doses of phenytoin in all the 
four trials of treated adult. 
 Therefore, the fruit fly offers remarkable biological 
similarity to humans, as a sophisticated genetic tool to 
screen drugs and drug targets4. Phenytoin exhibits  
adverse health effects at high doses or after chronic use 
by humans and is lethal when added to the diet of Droso-
phila. 
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